Zhenghong Gao

Company: Zhongmou Therapeutics

Job title: Chief Strategy Officer

Seminars:

Vision Restoration via Mutation-Agnostic Optogenetic Therapy: ZM-02 Opportunity 1:45 pm

Introducing ZM-02 optogenetic therapy enabling light-sensitive protein expression to restore vision to patients with severe retinal degeneration Delivering a mutation-agnostic approach allowing treatment across genetic profiles to broaden access for diverse patient populations Showcasing first-in-human clinical data demonstrating safety and functional vision improvement to validate ZM-02’s therapeutic potentialRead more

day: Conference Day One